Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy |
| terminated |
| Phase 2 |
| 12 |
| International Extranodal Lymphoma Study Group (IELSG)OTHER |
| 1 |
| Mar 30, 2015 |
| clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | terminated | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | terminated | Phase 2 | 22 | Centre Leon BerardOTHER | 1 | Jul 10, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | terminated | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | terminated | Phase 2 | 14 | Duke UniversityOTHER | 1 | May 12, 2014 | clinicaltrials |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | terminated | Phase 2 | 7 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Apr 1, 2014 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | terminated | Phase 2 | 25 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | terminated | Phase 2 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Dec 12, 2012 | clinicaltrials |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 20 | David RizzieriOTHER | 1 | Nov 28, 2012 | clinicaltrials |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 25 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 13 | Piramal Enterprises LimitedINDUSTRY | 2 | Jul 27, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00107614 | DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients | terminated | Phase 2 | 12 | University of ArkansasOTHER | 1 | Aug 26, 2011 | clinicaltrials |
| NCT00386321 | Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 10 | Chulalongkorn UniversityOTHER | 1 | Nov 18, 2010 | clinicaltrials |
| NCT00136591 | A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma | terminated | Phase 2 | 87 | Lymphoma Study AssociationOTHER | 2 | Oct 26, 2010 | clinicaltrials |
| NCT00275262 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | May 6, 2010 | clinicaltrials |
| NCT00474188 | A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 26 | Celgene CorporationINDUSTRY | 3 | Sep 2, 2009 | clinicaltrials |
| NCT00180895 | Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL | terminated | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 11, 2006 | clinicaltrials |
| NCT00083473 | A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia | terminated | Phase 2 | 28 | Titan PharmaceuticalsINDUSTRY | 1 | Aug 30, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2015source: clinicaltrials